The FDA approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism following hip or knee replacements and for the prevention of stroke in patients with nonvalvular atrial fibrillation.
Sylvester O. Agbahiwe, PharmD, Chukwudiebere Okeke, PharmD Candidate
Advertisement
Articles by Sylvester O. Agbahiwe, PharmD, Chukwudiebere Okeke, PharmD Candidate
Advertisement
Latest Updated Articles
- Janssen Pharmaceuticals' Xarelto
Published: December 7th 2011 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
3
Improving RSV Vaccine Coverage Could Prevent Thousands of Severe Cases in Older Adults
4
Recognizing Immunizing Pharmacists in the Community
5
